Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05757531 · ClinicalTrials.gov registry record · Phase 1
A Study of Carbon-14-Labelled [14C] LY3437943 in Healthy Male Participants
A Phase 1 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 7
- Enrollment target
NCT05757531: Completed Phase 1 study, sponsored by Eli Lilly and Company.
NCT05757531 is a Phase 1 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 7 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (88% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05757531, a Phase 1 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 7 participants
- Enrollment target
Study Summary
The main purpose of this study is to is to look at how much LY3437943 gets into the bloodstream and how long the body takes to get rid of it in healthy male participants. This study will involve a single dose of 14C radiolabeled LY3437943. his means that a radioactive tracer substance, C14, will be incorporated into the study drug to investigate the study drug and its breakdown products and to find out how much of these pass from blood into urine, feces and expired air. The study will last up to approximately 15 weeks including the screening period of 28 days.
Primary Outcome
Urinary Excretion of LY3437943 Radioactivity Over Time Expressed as a Percentage of the Total Radioactive Dose Administered
Interventions
- DRUG [¹⁴C]-LY3437943
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2023-03-17 |
| Est. Completion | 2023-06-23 |
| Phase | Phase 1 |
What the finished NCT05757531 record still lists
NCT05757531 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 7 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (88% lower).
The record links to 0 conditions, and to 1 intervention - of which [¹⁴C]-LY3437943 is the first listed.
NCT05757531 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05757531 about?
NCT05757531 is a clinical study titled "A Study of Carbon-14-Labelled [14C] LY3437943 in Healthy Male Participants". The main purpose of this study is to is to look at how much LY3437943 gets into the bloodstream and how long the body takes to get rid of it in healthy male participants. This study will involve a single dose of 14C radiolabeled LY3437943. his means that a radioactive tracer substance, C14, will be ...
What is the current status of trial NCT05757531?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 7 participants. The study started on 2023-03-17. Estimated completion is 2023-06-23.
What interventions are being tested in trial NCT05757531?
The interventions under investigation include: [¹⁴C]-LY3437943 (DRUG).
Who is sponsoring clinical trial NCT05757531?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05757531's enrollment target sits among peer trials
7 1972nd of 2000 higher than 27 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI